Vintafolide is a novel folate receptor (FR)-targeted agent that has demonstrated clinical activity and a good toxicity profile in patients with ovarian cancer and adenocarcinoma of the lung.

A phase 1 trial evaluating FSHR-targeting CAR T cells for patients with ovarian cancer has dosed the first patient in its ...

An NDA has been accepted by the FDA for the combination of avutometinib and defactinib in KRAS-mutated recurrent low-grade ...

These findings could lead to personalized therapies that target the right patients at the right time, offering hope for improving care for ovarian cancer—a highly aggressive and common malignancy.

Experts say ovarian cancer causes more deaths than all other female reproduction system cancers and is difficult to diagnose ...

The US Food and Drug Administration (FDA) has accepted for priority review the new drug application (NDA) for avutometinib to be used in combination with defactinib for the treatment of adults with ...

BTIG raised the firm’s price target on Verastem (VSTM) to $20 from $13 and keeps a Buy rating on the shares after the company announced the FDA ...

There are many targeted drugs already available to treat ... reduced cancer growth and improved survival in models of ovarian cancer. The drug works by masking the expression of the Flower-Lose ...

The Minnesota Department of Health (MDH) says about 3,850 women in Minnesota are living with an ovarian cancer diagnosis and ...

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under Priority Review for avutometinib, in combination with defactinib, for the treatment of adults with ...